CRO giant Charles River Laboratories ended 2014 with a bang, boosting revenue by about 14% in the fourth quarter to close a deal-filled year.
Charles River Laboratories has extended its partnership with CHDI Foundation, signing up for 5 more years of work spotlighting new treatments for Huntington's disease.
A string of acquisitions has revenue rolling at Charles River Laboratories, and the CRO has inked another M&A deal it hopes will pay off with a larger market share.
Charles River Laboratories has unveiled a new technology it says can better test for impurities by combining two common methods into a single product, making for a flexible solution.
AstraZeneca is moving forward with a respiratory candidate developed alongside Charles River Laboratories' discovery business, a milestone the CRO says affirms its investments in the space.
Charles River Laboratories is dialing up its expectations for the year after some M&A padded its second-quarter results, riding a 16.5% boost in sales.
The National Cancer Institute is terminating a $34 million mouse-model contract with Charles River Laboratories, possibly imperiling jobs at one of the CRO's Maryland outposts.
Charles River Laboratories posted a slight increase in sales last quarter, crediting a rise in preclinical demand as it counts on some new acquisitions to brighten 2014.
Charles River Laboratories has closed its bid for two CROs formerly owned by drug developer Galapagos, trading $179 million up front and up to $7 million down the line for Argenta and BioFocus.
Belgian biotech Galapagos is getting out of the CRO business, selling off its two contract units to preclinical giant Charles River Laboratories for $179 million and planning to put the proceeds into its pipeline.